Equities
Health CareMedical Equipment and Services
  • Price (CHF)55.00
  • Today's Change0.00 / 0.00%
  • Shares traded1.11k
  • 1 Year change+0.73%
  • Beta0.8446
Data delayed at least 15 minutes, as of Feb 16 2026 13:26 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Coltene Holding AG is a Switzerland-based Company active in the healthcare sector. It develops, manufactures and sells dental consumables and small equipment focusing on mechanical instruments and filling materials. It has production facilities in Switzerland, the United States, Germany and Hungary. The Company's product range comprises six product groups: Adhesives / Restoratives; Endodontics; Prosthetics; Rotary Instruments; Treatment Auxiliaries; and Hygiene. Coltene Holding AG has a number of wholly owned subsidiaries active in production and sales of dental specialties based in Switzerland, Germany, Hungary, Canada, the United Kingdom, France, China, India, the United States and Brazil.

  • Revenue in CHF (TTM)240.71m
  • Net income in CHF14.31m
  • Incorporated2005
  • Employees1.18k
  • Location
    Coltene Holding AGFeldwiesenstrasse 20ALTSTAETTEN 9450SwitzerlandCHE
  • Phone+41 717575380
  • Fax+41 717575301
  • Websitehttps://www.coltene.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Median Technologies SA21.24m-20.03m182.66m211.00------8.60-1.16-1.161.23-2.080.8894-12.983.9296,717.84-83.91-60.70---232.35102.73102.32-94.35-97.730.3543-26.56----3.2520.72-9.83--43.77--
Affluent Medical SAS3.75m-13.43m194.31m76.00--6.71--51.79-0.3759-0.37590.10510.53650.0709--0.954159,681.16-25.40-23.76-32.61-27.591.34-226.93-358.01-1,815.40---924.300.5030------5.84------
Prim SA219.08m13.26m201.01m954.0014.111.668.650.91750.91760.917614.137.801.171.974.17251,008.807.096.2710.408.5038.7737.706.055.851.20144.870.139963.107.689.08-13.83-0.536613.506.35
Tristel Plc48.68m6.96m210.89m265.0030.376.0721.324.330.13830.13830.96760.69151.041.935.81175,328.3014.859.6017.5711.0980.6280.9014.2911.042.96--0.1512120.7110.807.962.335.42-3.5918.10
Onward Medical NV1.01m-35.21m211.26m102.00--6.67--208.52-0.866-0.8660.02490.62090.0215--9.1110,901.96-74.86-55.03-92.84-61.1977.16---3,475.81-39,652.374.30-17.130.352--236.76--1.26--3.88--
Stratec SE234.06m14.26m220.65m1.42k15.471.017.020.94271.291.2921.1319.750.58251.325.65177,177.203.556.724.247.9629.0928.416.099.631.656.850.355237.35-4.733.764.242.35-7.49-6.51
Medistim ASA54.03m11.51m286.01m154.0024.788.4320.955.297.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB65.30m13.17m314.78m236.0023.904.1219.024.826.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
COLTENE Holding AG240.71m14.31m328.66m1.18k22.963.6315.601.372.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
IVF Hartmann Holding AG159.45m19.02m348.00m309.0018.312.3914.382.187.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA543.58m15.49m425.43m2.10k27.163.8015.840.78270.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Revenio Group Oyj99.95m15.85m452.14m247.0028.444.3122.764.520.6540.6544.124.310.75153.057.26444,129.6011.9214.0014.2317.4070.9270.9515.8619.381.639.660.0969--5.9712.43-5.935.4222.19--
Lumibird SA196.75m9.77m476.93m1.07k48.802.6217.202.420.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
medmix AG468.10m-5.80m481.12m2.67k--1.129.881.03-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
RaySearch Laboratories AB (publ)115.65m19.60m491.28m458.0027.896.4511.014.256.656.6539.2528.740.65846.252.932,935,074.0011.165.2616.217.7792.4291.0116.949.701.6664.920.286152.3812.7715.5811.93--0.2213--
Data as of Feb 16 2026. Currency figures normalised to Coltene Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

15.57%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 06 Oct 2025296.89k4.97%
Reichmuth & Co.as of 18 Sep 2025180.00k3.01%
Tweedy, Browne Co. LLCas of 28 Nov 2025148.68k2.49%
LLB Asset Management AGas of 31 Dec 202578.50k1.31%
Mandatum Asset Management Ltd.as of 30 Jun 202554.01k0.90%
Dimensional Fund Advisors LPas of 05 Feb 202644.19k0.74%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202541.77k0.70%
Investor Asset Management BVas of 06 Feb 202635.00k0.59%
Valiant Bank AGas of 31 Dec 202528.90k0.48%
Swiss Rock Asset Management AGas of 31 Jan 202622.11k0.37%
More ▼
Data from 30 Jun 2025 - 06 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.